PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?

Abstract The current approach of morbidity control of schistosomiasis, a helminth disease of poverty with considerable public health and socioeconomic impact, is based on preventive chemotherapy with praziquantel. There is a pressing need for new drugs against this disease whose control entirely depends on this single drug that has been widely used over the past 40 years. We argue that a broader anthelminthic approach supplementing praziquantel with new antischistosomals targeting different parasite development stages would not only increase efficacy but also reduce the risk for drug resistance. Repositioning drugs already approved for other diseases provides a shortcut to clinical trials, as it is expected that such drugs rapidly pass the regulatory authorities. The antischistosomal properties of antimalarial drugs (e.g., semisynthetic artemisinins, synthetic trioxolanes, trioxaquines and mefloquine) and of drugs being developed or registered for other purposes (e.g., moxidectin and miltefosin), administered alone or in combination with praziquantel, have been tested in the laboratory and clinical trials. Another avenue to follow is the continued search for new antischistosomal properties in plants. Here, we summarise recent progress made in schistosomiasis chemotherapy, placing particular emphasis on repositioning of existing drugs against schistosomiasis.
PMID
Related Publications

Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis.

Drugs for treating urinary schistosomiasis.

Schistosomiasis control: praziquantel forever?

Something old, something new: is praziquantel enough for schistosomiasis control?

Antimalarials in the treatment of schistosomiasis.

Authors

Mayor MeshTerms
Keywords

Chemotherapy

Drug repositioning

Elimination

Morbidity control

Praziquantel

Schistosomiasis

Journal Title infectious diseases of poverty
Publication Year Start




PMID- 28351414
OWN - NLM
STAT- MEDLINE
DA  - 20170329
DCOM- 20170411
LR  - 20170411
IS  - 2049-9957 (Electronic)
IS  - 2049-9957 (Linking)
VI  - 6
IP  - 1
DP  - 2017 Mar 28
TI  - Controlling schistosomiasis with praziquantel: How much longer without a viable
      alternative?
PG  - 74
LID - 10.1186/s40249-017-0286-2 [doi]
AB  - The current approach of morbidity control of schistosomiasis, a helminth disease 
      of poverty with considerable public health and socioeconomic impact, is based on 
      preventive chemotherapy with praziquantel. There is a pressing need for new drugs
      against this disease whose control entirely depends on this single drug that has 
      been widely used over the past 40 years. We argue that a broader anthelminthic
      approach supplementing praziquantel with new antischistosomals targeting
      different parasite development stages would not only increase efficacy but also
      reduce the risk for drug resistance. Repositioning drugs already approved for
      other diseases provides a shortcut to clinical trials, as it is expected that
      such drugs rapidly pass the regulatory authorities. The antischistosomal
      properties of antimalarial drugs (e.g., semisynthetic artemisinins, synthetic
      trioxolanes, trioxaquines and mefloquine) and of drugs being developed or
      registered for other purposes (e.g., moxidectin and miltefosin), administered
      alone or in combination with praziquantel, have been tested in the laboratory and
      clinical trials. Another avenue to follow is the continued search for new
      antischistosomal properties in plants. Here, we summarise recent progress made in
      schistosomiasis chemotherapy, placing particular emphasis on repositioning of
      existing drugs against schistosomiasis.
FAU - Bergquist, Robert
AU  - Bergquist R
AD  - Ingerod, Brastad, Sweden.
FAU - Utzinger, Jurg
AU  - Utzinger J
AD  - Swiss Tropical and Public Health Institute, P.O. Box, CH-4002, Basel,
      Switzerland.
AD  - University of Basel, P.O. Box, CH-4003, Basel, Switzerland.
FAU - Keiser, Jennifer
AU  - Keiser J
AD  - Swiss Tropical and Public Health Institute, P.O. Box, CH-4002, Basel,
      Switzerland. [email protected]
AD  - University of Basel, P.O. Box, CH-4003, Basel, Switzerland.
      [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170328
PL  - England
TA  - Infect Dis Poverty
JT  - Infectious diseases of poverty
JID - 101606645
RN  - 0 (Anthelmintics)
RN  - 0 (Antimalarials)
RN  - 6490C9U457 (Praziquantel)
SB  - IM
MH  - Animals
MH  - Anthelmintics/pharmacology/therapeutic use
MH  - Antimalarials/administration & dosage/pharmacology/therapeutic use
MH  - Drug Repositioning
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Praziquantel/pharmacology/*therapeutic use
MH  - Public Health
MH  - Schistosoma/drug effects
MH  - Schistosomiasis/*drug therapy/*prevention & control
PMC - PMC5371198
OTO - NOTNLM
OT  - Chemotherapy
OT  - Drug repositioning
OT  - Elimination
OT  - Morbidity control
OT  - Praziquantel
OT  - Schistosomiasis
EDAT- 2017/03/30 06:00
MHDA- 2017/04/12 06:00
CRDT- 2017/03/30 06:00
PHST- 2017/01/25 [received]
PHST- 2017/03/14 [accepted]
AID - 10.1186/s40249-017-0286-2 [doi]
AID - 10.1186/s40249-017-0286-2 [pii]
PST - epublish
SO  - Infect Dis Poverty. 2017 Mar 28;6(1):74. doi: 10.1186/s40249-017-0286-2.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>